Do you want to read an article? Please log in or register.
Real-World Exploration of LDL-Cholesterol Management in Patients with Atherosclerotic Cardiovascular Disease
Cardiovascular Risk and Diseases
RECOMMENDED
Related content
Heart, Artery and Coronary Diseases
Systemic inflammation and health outcomes in patients receiving treatment for atherosclerotic cardiovascular disease
Eur Heart J
Mazhar F, Faucon AL, Fu EL, Szummer KE, Mathisen J, Gerward S, Reuter SB, Marx N, Mehran R, Carrero JJ
doi: 10.1093/eurheartj/ehae557
Further Publications
Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Male and Female Patients: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial
JAMA Cardiol
Benziger CP, Stebbins A, Wruck LM, Effron MB, Marquis-Gravel G, Farrehi PM, Girotra S, Gupta K, Kripalani S, Munoz D, Polonsky TS, Sharlow A, Whittle J, Harrington RA, Rothman RL, Hernandez AF, Jones WS
doi: 10.1001/jamacardio.2024.1712
Cardiovascular Risk and Diseases
Bempedoic Acid Reduces the Risk of Major Adverse Cardiovascular Events Across Patient Subgroups
RECOMMENDED
Heart Failure
Association of sex with in-hospital management and outcomes of patients with heart failure: data from the REAL-HF registry: The impact of sex in patients hospitalized for heart failure
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
Am Heart J
Sanna GD, Erre GL, Cameli M, Guerra F, Pastore MC, Marini A, Campora A, Gironella P, Costamagna M, Mandoli GE, Casiraghi M, Scuteri A, Lisi M, Casu G, Deidda M, Dessalvi CC, REAL-HF investigators
doi: 10.1016/j.ahj.2024.08.018
RECOMMENDED
Cardiovascular Risk and DiseasesFurther Publications
Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial
★ 2
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
JAMA Cardiol
Klug EQ, Llerena S, Burgess LJ, Fourie N, Scott R, Vest J, Caldwell K, Kallend D, Stein EA, LIBERATE-HR Investigators
doi: 10.1001/jamacardio.2024.1659
Heart Failure
Real-world data on Empagliflozin and Dapagliflozin use in patients with HEART failure: The RED-HEART study
ESC Heart Fail
Kocabas U, Ergin I, Yavuz V, Altın C, Kaplan M, Yılmaz Öztekin GM, Doğduş M, Murat S, Murat B, Kıvrak T, Karabulut D, Kaya E, Özdemir İH, Yıldız C, Salkın FÖ, Özçalık E, Polatkan ŞG, Çakan F, Şen T, Karabulut U, Çakal S, Oflar E, Sinan ÜY, Yenerçağ M, Türk UÖ
doi: 10.1002/ehf2.15049
Cardiovascular Risk and DiseasesFurther Publications
Exploring the Link Between Genetic Predictors of Cardiovascular Disease and Psoriasis
JAMA Cardiol
Ramessur R, Saklatvala J, Budu-Aggrey A, Ostaszewski M, Möbus L, Greco D, Ndlovu M, Mahil SK, Barker JN, Brown S, Paternoster L, Dand N, Simpson MA, Smith CH
doi: 10.1001/jamacardio.2024.2859
Cardiovascular Risk and Diseases
Population-level impact of semaglutide 2.4 mg in patients with obesity or overweight and cardiovascular disease: A modelling study based on the SELECT trial
Diabetes Obes Metab
Nanna MG, Doan QV, Fabricatore A, Faurby M, Henry AD, Houshmand-Oeregaard AS, Levine A, Navar AM, Scassellati Sforzolini T, Toliver JC
doi: 10.1111/dom.16370
RECOMMENDED
Cardiovascular Risk and Diseases
Risk of Atherosclerotic Cardiovascular Disease Hospitalizations after COPD Hospitalization among Older Adults
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Ann Am Thorac Soc
Mosher CL, Osazuwa-Peters OL, Nanna MG, MacIntyre NR, Que LG, Jones S, Palmer SM, O'Brien EC
doi: 10.1513/AnnalsATS.202401-017OC